5 completed, 2 unknown, 1 suspended, 1 terminated. 9 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 9 | Completed 5, Unknown 2, Suspended 1, Terminated 1 |
Follow Indapamide: new trials by email Literature Review of Indapamide trials Research Report on Indapamide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of BR1015 Combination Therapy Fimasartan + Indapamide, Fimasartan + Indapamide placebo - Essential Hypertension | Phase 3 | Completed | Boryung Pharmaceutical Co., Ltd | 248 | 2022-11-09 | 2024-12-20 |
| Efficacy and Safety Study of the Fixed-dose Combination of Olmesartan + Indapamide When Compared to the Isolated Drugs in the Treatment of Hypertension. fixed-dose of olmesartan 20mg/40 mg + indapamide 1,5 mg, Isolated drugs Olmesartan (20 mg or 40 mg) and Indapamide (1,5 mg) - Hypertension, Hypertension,Essential | Phase 3 | Unknown | Brainfarma Industria Química e Farmacêutica S/A | 400 | 2022-08-01 | 2022-03-21 |
| Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg, telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg, Telmisartan 20 mg/amlodipine 2.5 mg - Hypertension | Phase 3 | Completed | George Medicines PTY Limited | 1385 | 2021-07-09 | 2025-06-03 |
| Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg, Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg, Placebo - Hypertension | Phase 3 | Completed | George Medicines PTY Limited | 755 | 2021-06-14 | 2025-06-03 |
| Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension AGSAVI, AGLS - Hypertension | Phase 3 | Unknown | Ahn-Gook Pharmaceuticals Co.,Ltd | 306 | 2021-02-01 | 2020-12-29 |
| Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT) Cognitive Sub-Study telmisartan 20mg + amlodipine 2.5mg +indapamide 1.25mg, Placebo oral capsule - Cognitive Decline, Intracerebral Hemorrhage | Phase 3 | Terminated | The George Institute | 1 | 2020-02-27 | 2021-04-01 |
| Comparison of Losartan Associated With Indapamide Versus Hyzaar® in the Hypertension Treatment Indapamide / Losartan, Hyzaar® - Hypertension | Phase 3 | Suspended | EMS | 636 | 2019-11-27 | 2022-07-27 |
| Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg, Placebo - Intracerebral Haemorrhage (ICH), Hypertension | Phase 3 | Completed | The George Institute | 1671 | 2017-09-28 | 2025-09-12 |
| Fimasartan in the Senior Subjects Fimasartan or Fimasartan/Hydrochlorothiazide, Perindopril or Perindopril/Indapamide - The Elderly (≥ 70 Years) With Essential Hypertension | Phase 3 | Completed | Boryung Pharmaceutical Co., Ltd | 241 | 2016-07-15 | 2020-03-23 |
Hypertension (7) · Cerebral Hemorrhage (2) · Essential Hypertension (2) · Cerebral Small Vessel Diseases (1) · Cognitive Dysfunction (1) · Dementia, Vascular (1) · Hemorrhagic Stroke (1) · Stroke (1)
Boryung Pharmaceutical Co., Ltd (2) · George Medicines PTY Limited (2) · The George Institute (2) · Ahn-Gook Pharmaceuticals Co.,Ltd (1) · Brainfarma Industria Química e Farmacêutica S/A (1) · EMS (1)
Australia (4) · Sri Lanka (3) · United Kingdom (3) · Brazil (2) · Netherlands (2) · Nigeria (2) · South Korea (2) · United States (2) · Czechia (1) · Georgia (1) · Malaysia (1) · New Zealand (1) · Poland (1) · Singapore (1) · Taiwan (1)
Anthony Rodgers, Professor (2) · Craig Anderson (1) · Prof Craig Anderson (1) · Prof Sharon Naismith (1)
PMID 31262348, PMID 34022170, PMID 34503866, PMID 34994269, PMID 39217570, PMID 39426836, PMID 41180852, PMID 42019018, PMID 42163997